LabCorp (LH)

Executive Summary

LabCorp (NYSE: LH) is a leading global life sciences company that operates through two core segments: Diagnostic Laboratories and Drug Development (Covance). The Diagnostic Laboratories business offers a comprehensive range of clinical lab tests, serving patients, providers, and health systems. The Drug Development segment provides central lab services, clinical trial management, and contract research to biopharma companies. Leveraging its integrated model, LabCorp connects diagnostic insights with drug development expertise to accelerate the path from discovery to patient care. The company maintains a stable revenue base from recurring diagnostic services and benefits from long-term trends in healthcare spending, aging populations, and precision medicine. Looking ahead, LabCorp is well-positioned to capitalize on expanding demand for clinical testing and drug development outsourcing. The company continues to invest in automation, AI-driven diagnostics, and high-value specialty testing, particularly in oncology and neurology. Despite near-term margin pressures from inflation and lab volume normalization, LabCorp's diversified business model supports consistent cash flow and shareholder returns through buybacks and dividends. The conviction score of 65 reflects a balanced view of steady core operations offset by modest growth headwinds and limited near-term catalysts from the internal pipeline.

Upcoming Catalysts (preview)

• Q2 2026Q2 2026 Earnings Release100% success
• H2 2026EMB-01 Phase 1/2 Data Update in Solid Tumors50% success
• Q3 2026FDA Clearance for Alzheimer's Blood Test70% success